Why commercialization of gene therapy stalled; Examining the life cycles of gene therapy technologies

Gene Therapy

Volumn 21, Issue 2, 2014, Pages 188-194

  Ledley, F D ^a   McNamee, L M ^a   Uzdil, V ^a   Morgan, I W ^a  

^a BENTLEY UNIVERSITY   (United States)

Author keywords

Biotechnology; Capital investment; Drug development; Innovation; Technology life cycles

Indexed keywords

BIOMETRY; BIOTECHNOLOGY; GENETIC THERAPY; HUMANS;

EID: 84893717170     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.72     Document Type: Article

References (50)

1. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science 1972; 175: 949-955.
2. Wirth T, Yla-Herttuala S, Parker N. History of gene therapy. Gene 2013; 10: 162-169.
3. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH et al. Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 2007; 14: 1439-1447.
4. Alton E, Alexander BL, Ali RR, Bainbridge JW, Braun S, Cheng SH et al. Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 2007; 14: 1439-1447.
5. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007; 9: 833-842.
6. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
7. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
8. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
9. Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013; 120: 1283-1291.
10. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-364.
11. Naldini L. Medicine. A comeback for gene therapy. Science 2009; 326: 805-806.
12. Persidis A, Tomczyk MS. Critical issues in gene therapy commercialization. Nat Biotechnol 1997; 15: 689-690.
13. Guo J, Xin H. Chinese gene therapy. Splicing out the West? Science 2006; 314: 1232-1235.
14. IuV C, Staroverov I, Nersesian E, Isaev A, Deev R. [Therapeutic angiogenesis in treatment of patients with chronic obliterating diseases of lower limb arteries]. Angiol Sosud Khir 2011; 18: 19-27.
15. Gruber K. Europe gives gene therapy the green light. Lancet 2012; 380: e10.
16. Buning H. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med 2013; 5: 1-3.
17. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013; 20: 361-369.
18. Salonius K, Simard N, Harland R, Ulmer JB. The road to licensure of a DNA vaccine. Curr Opin Investig Drugs 2007; 8: 635-641.
19. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011; 72: 1631-1638.
20. McNamee LM, Ledley FD. Making the biotech IPO work. Nat Biotechnol 2013; 31: 5-6.
21. Brown PA, Khan AS, Draghia-Akli R, Pope MA, Bodles-Brakhop AM, Kern DR. Effects of administration of two growth hormone-releasing hormone plasmids to gilts on sow and litter performance for the subsequent three gestations. Am J Vet Res 2012; 73: 1428-1434.
22. Johnson MW, Christensen CM, Kagermann H. Reinventing your business model. Harvard Bus Rev 2008; 86: 57-68.
23. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-716.
24. Orkin SH, Motulsky AG. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy 7. NIH: Maryland, 1995.
25. Schoonhoven CB, Eisenhardt KM, Lyman K. Speeding products to market: Waiting time to first product introduction in new firms. AdminSci Quart 1990 177-207.
26. Wheeler SS, Langevin S, Woods L, Carroll BD, Vickers W, Morrison SA et al. Efficacy of three vaccines in protecting western Scrub-Jays (Aphelocoma californica) from experimental infection with West Nile virus: Implications for vaccination of island Scrub-Jays (Aphelocoma insularis). Vector Borne Zoonotic Dis 2011; 11: 1069-1080.
27. McNamee LM, Ledley FD. Patterns of technological innovation in biotech. Nat Biotechnol 2012; 30: 937-943.
28. Smith SL. Ten years of orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 1996; 6: 109-119.
29. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-1078.
30. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4: 413-415.
31. Crofts C, Krimsky S. Emergence of a scientific and commercial research and development infrastructure for human gene therapy. Hum Gene Ther 2005; 16: 169-177.
32. Martin PA. Gene Therapy in Europe: exploitation and commercial development, studies on the socio-economic impact of biotechnology. Directorate-General for Research, European Commission: Brussels, 2001.
33. Jain K. A Special Report on Gene Therapy. Wiley: Hoboken, NJ, 2000.
34. Check E. Harmful potential of viral vectors fuels doubts over gene therapy. Nature 2003; 423: 573-574.
35. Gompers PA, Lerner J. The Venture Capital Cycle. MIT Press: Cambridge, MA, 2004.
36. Morgan Jr IW, Abetti PA. Private and public 'cradle to maturity' financing patterns of US biotech ventures (1970-2001). J PE 2004; 7: 9-25.
37. McDonald CL, Benson J, Cornetta K, Diggins M, Johnston JC, Sepelak S et al. Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP). Hum Gene Ther Clin Dev 2013; 24: 5-10.
38. Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011; 29: 121-128.
39. De Bie C. Genzyme: 15 years of cell and gene therapy research. Regen Med 2007; 2: 95-97.
40. Cavalla D. Architecture of R&D-a conceptual framework for collaboration. Drug Discov Today 1997; 2: 200-205.
41. Pisano GP. Science Business: The promise, the Reality, and the Future of Biotech. Harvard Business Press, 2006.
42. Guedj I, Scharfstein D. Organizational scope and investment: evidence from the drug development strategies and performance of biopharmaceutical firms. National Bureau of Economic Research 2004; NBER Working Paper No. 10933.
43. Metrick A, Nicholson S. Does financing have a real effect on drug development? 2006. Working Paper referenced with permission of authors.
44. Michael A. Financing gene therapy beyond phase II. Gene Ther 1996; 3: 1035.
45. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15: 65-77.
46. Agarwal P, Searls DB. Can literature analysis identify innovation drivers in drug discovery? Nat Rev Drug Discov 2009; 8: 865-878.
47. Garfield E, Melino G. The growth of the cell death field: an analysis from the ISI-Science citation index. Cell Death Differ 1997; 4: 352-361.
48. Marshall A. Trends in biotech literature 2008. Nat Biotechnol 2009; 27: 789.
49. Taroncher-Oldenburg G, Marshall A. Trends in biotech literature 2006. Nat Biotechnol 2007; 25: 961.
50. Taroncher-Oldenburg G, Marshall A. Trends in biotech literature 2007. Nat Biotechnol 2008; 26: 1062.